(:OPNT)

Feb 07, 2023 04:01 pm ET
Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today that the Committee on Foreign Investment in the United States (CFIUS) approved the previously announced Merger Agreement (the Agreement) for Opiant to be acquired by Indivior PLC (LSE:...
Feb 06, 2023 08:00 am ET
Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLC
Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant to be...
Jan 19, 2023 04:05 pm ET
Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for OPNT003, nasal nalmefene, Opiant’s product candidate for the...
Jan 08, 2023 08:47 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, CBIO
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Jan 06, 2023 06:28 pm ET
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Opiant Pharmaceuticals, Inc. (NasdaqCM: OPNT) to Indivior PLC. Under the terms of the proposed transaction, shareholders of Opiant will receive $20.00 in cash plus up to $8.00 per share in contingent value rights for each share of Opiant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Dec 14, 2022 09:23 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, FORG, USER
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Dec 10, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of ELVT, OPNT, WAFD, and LBC
Elevate Credit, Inc. (NYSE: ELVT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of ELVT to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are...
Dec 08, 2022 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, IMGO, SAL
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Dec 06, 2022 11:07 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, OPNT, BNFT, ABMD
NEW YORK, Dec. 6, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Dec 05, 2022 12:21 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc.
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Dec 01, 2022 10:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RBA, WAFD, OPNT, GRAY
NEW YORK, Dec. 1, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 30, 2022 07:46 pm ET
Lifshitz Law PLLC Announces Investigations of ELVT, OPNT, WAFD, and OYST
Elevate Credit, Inc. (NYSE: ELVT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of ELVT to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an...
Nov 27, 2022 10:26 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, MYOV
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Nov 22, 2022 04:01 pm ET
Opiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has completed submission of its rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for OPNT003, nasal nalmefene, for the...
Nov 22, 2022 10:10 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, OPNT
NEW YORK, Nov. 22, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 20, 2022 10:59 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates WAFD, LBC, OPNT
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Washington Federal, Inc. (NASDAQ:...
Nov 19, 2022 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of ELVT, OPNT, WAFD, and LBC
Elevate Credit, Inc. (NYSE: ELVT) Lifshitz Law PLLC announces investigation into possible breach of fiduciary duties in connection with the sale of ELVT to an affiliate of Park Cities Asset Management LLC for $1.87 per share. If you are an...
Nov 15, 2022 08:17 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, LBC
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Opiant Pharmaceuticals, Inc. (NASDAQ:...
Nov 14, 2022 09:25 pm ET
EQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNT
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Opiant Pharmaceuticals, Inc. (OPNT), relating to its proposed acquisition by Indivior PLC. Under the terms of the agreement, OPNT shareholders will receive $20.00 in cash plus up to $8.00 per share in CVRs per share they own. Click here f
Nov 14, 2022 06:46 pm ET
OPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant Pharmaceuticals, Inc. -
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Opiant Pharmaceuticals, Inc. (NasdaqCM: OPNT) to Indivior PLC. Under the terms of the proposed transaction, shareholders of Opiant will receive $20.00 in cash plus up to $8.00 per share in contingent value rights for each share of Opiant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Nov 14, 2022 03:43 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Opiant Pharmaceuticals, Inc.
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Opiant Pharmaceuticals, Inc. ("Opiant" or the "Company") (NASDAQ: OPNT), in connection with its takeover by Indivior PLC. Under the terms of the merger agreement, shareholders will receive $20.00 cash for each Opiant share, plus up to $8.00 per share in contingent value rights ("CVRs") if revenue milestones are achieved by Opiant's lead asset (OPNT003) in the seven years after the U.S. commercial launch of OPNT003. 
Nov 14, 2022 01:17 pm ET
OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant Pharmaceuticals
The law firm of Wohl & Fruchter LLP is investigating whether the directors of Opiant Pharmaceuticals, Inc. (Nasdaq: OPNT) (“Opiant”) acted in the best interests of Opiant shareholders in approving the sale of Opiant to Indivior for $20.00 per share...
Nov 14, 2022 11:30 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPNT, WAFD, LBC
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Nov 14, 2022 10:27 am ET
OPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT) to Indivior PLC is fair to Opiant shareholders. Per the agreement, Indivior would acquire Opiant for $20.00 per share in cash, plus up to $8.00 per share in contingent value rights that may become payable in the event that certain net revenue milestones are achieved during the relevant seven-year period by OPNT003 after its approval and launch.
Nov 14, 2022 09:37 am ET
Thinking about buying stock in Canopy Growth Corp, Starbucks, Opiant Pharmaceuticals, Phunware, or Ardelyx?
NEW YORK, Nov. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, SBUX, OPNT, PHUN, and ARDX.
Nov 14, 2022 09:25 am ET
Shareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with Indivior
MILWAUKEE, Nov. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating Opiant (NASDAQ: OPNT) for possible breaches of fiduciary duty and other violations of law in its transaction with Indivior. 
Nov 14, 2022 02:13 am ET
Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and nine months ended September 30, 2022....
Nov 14, 2022 02:12 am ET
Indivior PLC to Acquire Opiant Pharmaceuticals
Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) today announced that it has entered into a definitive merger agreement to be acquired by Indivior Inc, a subsidiary of Indivior PLC (LON: INDV). Under the terms of the agreement, Indivior will acquire all...
Nov 14, 2022 01:10 am ET
Indivior To Acquire Opiant Pharmaceuticals
Acquisition Strengthens and Extends Indivior's Position as a Leader in Addiction Treatment
Oct 27, 2022 04:05 pm ET
Opiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the third quarter ended...
Oct 06, 2022 08:01 am ET
Opiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the last patient has been enrolled in the Phase 2 clinical trial of OPNT002,...
Aug 22, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis Syndrome
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Opiant’s pipeline candidate OPNT004 (drinabant) for the treatment of cannabinoid...
Aug 12, 2022 07:30 am ET
MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors.
Aug 12, 2022 07:30 am ET
MindMed Strengthens Board with Appointment of Two New Independent Directors
NEW YORK, Aug. 12, 2022 /CNW/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors.
Aug 11, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months and six months ended June 30, 2022, and...
Aug 08, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Additional $2.1 Million Funding Under BARDA Contract for OPNT003, Nasal Nalmefene
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the Biomedical Advanced Research and Development Authority (BARDA) has awarded an additional approximately $2.1 million to support OPNT003, nasal nalmefene, for the...
Aug 02, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent With Claims Covering OPNT003 for the Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 16/461,354, with formulation and method of use claims around...
Aug 01, 2022 04:05 pm ET
Opiant Pharmaceuticals to Report Second Quarter 2022 Financial Results and Host Conference Call and Webcast on August 11, 2022
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced it will report its financial results for the second quarter ended...
Jun 28, 2022 04:05 pm ET
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation and Human Capital Committee of the Company’s Board...
Jun 08, 2022 04:05 pm ET
Opiant Pharmaceuticals and Aptar Pharma Expand Long-Term Collaboration for the Manufacture of Unidose Nasal Spray for OPNT003, Nasal Nalmefene
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced a capacity investment agreement with Aptar Pharma (Aptar), a leading provider of drug delivery systems, to expand production of Aptar’s nasal Unidose device, which will be used in...
Jun 01, 2022 04:05 pm ET
Opiant Pharmaceuticals Initiates Rolling Submission of New Drug Application to U.S. Food and Drug Administration for OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (Opiant) (NASDAQ: OPNT) today announced the filing of the first module of its New Drug Application (NDA) for OPNT003, nasal nalmefene, for the treatment of opioid overdose. The module was submitted pursuant to a rolling...
May 20, 2022 04:05 pm ET
Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), announced today that to protect the health and safety of its shareholders, employees, and communities amidst a rise locally in COVID-19, Opiant's 2022 Annual Meeting of Shareholders will be...
May 10, 2022 04:01 pm ET
Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a...
May 03, 2022 08:00 am ET
Opiant Pharmaceuticals to Report First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 10, 2022
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, will report its financial results for the first quarter ended March 31, 2022, after the financial...
Apr 29, 2022 12:47 pm ET
Opiant Pharmaceuticals Issues Statement in Response to Fake Press Release
SANTA MONICA, Calif., April 29, 2022 /PRNewswire/ -- Opiant Pharmaceuticals (NASDAQ: OPNT) was the subject of a fake news release issued on Friday, April 29, 2022, that falsely stated Opiant announced a partnership with Hikma Pharmaceuticals, PLC. 
Apr 27, 2022 04:01 pm ET
Opiant Pharmaceuticals Announces Positive Topline Results from Head-to-Head Pharmacodynamic Study Comparing OPNT003, Nasal Nalmefene, to Nasal Naloxone
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a pharmacodynamic (“PD”) study for OPNT003, nasal nalmefene, (3mg nalmefene hydrochloride), an investigational treatment for opioid overdose. This...
Mar 15, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and twelve months ended December 31, 2021, and...
Mar 10, 2022 04:01 pm ET
Opiant Pharmaceuticals to Participate in 32nd Oppenheimer Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Chief Executive Officer, Dr. Roger Crystal, will participate in a fireside...
Mar 07, 2022 04:05 pm ET
Opiant Pharmaceuticals to Report Fourth Quarter 2021 Financial Results and Host Conference Call and Webcast on March 15, 2022
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates on Tuesday,...
Feb 10, 2022 08:00 am ET
Opiant Pharmaceuticals Announces Positive Pharmacokinetic, Safety, and Tolerability Results From a Multi-Dose Study for OPNT003, Nasal Nalmefene
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose. The crossover design...
Jan 24, 2022 04:05 pm ET
Opiant Pharmaceuticals Announces Additional $2.2 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support OPNT003,...
Jan 20, 2022 05:48 pm ET
Opiant Pharmaceuticals Announces First Patient Dosed in Phase 2 Trial of OPNT002, Nasal Naltrexone, for Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the first patient has been dosed in a Phase 2 clinical trial of OPNT002, nasal naltrexone, for the treatment of Alcohol Use Disorder (“AUD”). The trial will determine...
Jan 20, 2022 05:45 pm ET
Correction: Opiant Pharmaceuticals Corrects Error in Issuing Duplicate Press Release Today
Correction: Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, reports that the company mistakenly reissued the press release this...
Jan 20, 2022 04:05 pm ET
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Committee of the Company’s Board of Directors has...
Dec 20, 2021 04:05 pm ET
Opiant Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opiant Pharmaceuticals, Inc. (“Opiant” or “Company”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the Compensation Committee of the Company’s Board of Directors has...
Nov 11, 2021 04:05 pm ET
Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and nine months ended September 30, 2021, and...
Nov 10, 2021 04:05 pm ET
Opiant Pharmaceuticals to present at Jefferies Virtual London Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that members of the company’s senior management team will participate in the 12th Jefferies London...
Nov 04, 2021 04:05 pm ET
Opiant Receives FDA Fast Track Designation for OPNT003, Nasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced that the U.S. Food and Drug Administration (“FDA”) has granted fast track designation for OPNT003,...
Nov 02, 2021 04:05 pm ET
Opiant Announces Publication of Manuscript Treatment of Overdose in the Synthetic Opioid Era in Peer-Reviewed Journal Pharmacology & Therapeutics
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a company advancing medicines to better treat addictions and drug overdose, today announced the publication of a manuscript entitled “Treatment of Overdose in the Synthetic Opioid Era”...
Oct 21, 2021 04:05 pm ET
Opiant Pharmaceuticals to Report Third Quarter 2021 Financial Results and Host Conference Call and Webcast on November 11, 2021
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report third quarter 2021 financial results and pipeline updates on Thursday,...
Aug 25, 2021 04:05 pm ET
Opiant Pharmaceuticals to Participate in September Investor Conferences
Opiant Pharmaceuticals, Inc. (“Opiant”) (Nasdaq: OPNT) today announced that members of the company’s senior management team will participate in the following virtual investor conferences: H.C. Wainwright 23rd Annual Global Investment...
Aug 05, 2021 04:01 pm ET
Opiant Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three and six months ended June 30, 2021, and provided a...
Jul 22, 2021 04:05 pm ET
Opiant Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call and Webcast on August 5, 2021
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the second quarter ended June 30, 2021, after...
Jul 20, 2021 04:05 pm ET
Opiant Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to two...
Jul 12, 2021 08:00 am ET
Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Matthew Ruth as Chief Commercial Officer. Mr. Ruth brings...
Jul 07, 2021 09:31 am ET
Thinking about buying stock in Opiant Pharmaceuticals, RealNetworks, Vaxart, Clover Health, or Viewray?
NEW YORK, July 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPNT, RNWK, VXRT, CLOV, and VRAY.
Jul 06, 2021 04:01 pm ET
Opiant Pharmaceuticals Announces Positive Top-line Results of Confirmatory Pharmacokinetic (PK) Study for OPNT003, Nasal Nalmefene, a Novel Investigational Treatment for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive top-line results from its confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for opioid overdose. The study was conducted in 68 healthy subjects...
May 24, 2021 04:05 pm ET
Opiant Pharmaceuticals to Present at the 2021 Jefferies Virtual Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present at the Jefferies...
May 18, 2021 04:05 pm ET
Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns relating to the coronavirus...
May 11, 2021 04:05 pm ET
Opiant Pharmaceuticals Announces First Quarter 2021 Financial Results and Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2021, and provided a...
May 03, 2021 04:01 pm ET
Opiant Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the first quarter ended March 31, 2021, after...
Apr 05, 2021 04:01 pm ET
Opiant Pharmaceuticals Announces First Subjects Dosed in Study Comparing OPNT003, Nasal Nalmefene, With Nasal Naloxone
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that the first subjects were dosed in a head-to-head clinical study comparing the...
Mar 31, 2021 04:01 pm ET
Opiant Pharmaceuticals Announces Final Tranche of NIDA Grant Award for its Investigational Treatment for Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of...
Mar 22, 2021 04:01 pm ET
Opiant Pharmaceuticals Strengthens Board of Directors With Appointment of Seasoned Clinical Development Executive Lorianne Masuoka, M.D.
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka, M.D., to its Board of Directors, effective...
Mar 04, 2021 04:05 pm ET
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2020 and...
Feb 22, 2021 04:01 pm ET
Opiant Pharmaceuticals to Report Fourth Quarter 2020 Financial Results and Host Conference Call and Webcast on March 4, 2021
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended December...
Feb 08, 2021 04:01 pm ET
Opiant Pharmaceuticals Announces First Patient Dosed in Confirmatory Pharmacokinetic Study Assessing OPNT003, Nasal Nalmefene, for the Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose. Results from the study are...
Dec 14, 2020 04:01 pm ET
Opiant Pharmaceuticals Announces Additional $3.5 million Funding Under BARDA Contract for OPNT003 Nasal Nalmefene Development Program
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced an additional commitment of up to $3.5 million from the Biomedical Advanced Research and Development Authority (“BARDA”), part of the Office of the Assistant Secretary for...
Dec 10, 2020 04:01 pm ET
Opiant Pharmaceuticals Secures $50 Million in Convertible Debt Financing
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it has entered into a $50 million convertible Note Purchase and Security...
Dec 07, 2020 04:01 pm ET
Opiant Pharmaceuticals Announces Appointment of Biopharmaceutical Leader Craig A. Collard as Chairman to its Board of Directors
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today the appointment of Craig A. Collard, a seasoned biopharmaceutical leader with...
Nov 12, 2020 04:05 pm ET
Opiant Pharmaceuticals Announces Third Quarter 2020 Financial Results and Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended September 30, 2020, and provided a...
Nov 02, 2020 04:01 pm ET
Opiant Pharmaceuticals to Participate at the Jefferies 2020 Virtual London Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to present its...
Oct 29, 2020 04:05 pm ET
Opiant Pharmaceuticals Partners with Aptar Pharma for Nasal Nalmefene Opioid Overdose Treatment
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced it has entered into an agreement with drug delivery specialist Aptar Pharma (“Aptar”), for the development of OPNT003 nasal nalmefene for use in conjunction with Aptar’s Unit...
Oct 27, 2020 04:01 pm ET
Opiant Pharmaceuticals to Report Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 12, 2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its third quarter 2020 financial results after the financial markets...
Aug 31, 2020 04:05 pm ET
Opiant Pharmaceuticals to Participate at the 2020 Cantor Global Virtual Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, is scheduled to participate in a...
Aug 06, 2020 04:05 pm ET
Opiant Pharmaceuticals Announces Second Quarter 2020 Financial Results and Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended June 30, 2020, and provided a...
Jul 23, 2020 04:01 pm ET
Opiant Pharmaceuticals to Report Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 6, 2020
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its second quarter 2020 financial results after the financial markets...
Jun 05, 2020 09:37 pm ET
Opiant Pharmaceuticals Statement on U.S. District Court Decision
Today, the U.S. District Court for the District of New Jersey entered a decision in the patent litigation regarding NARCAN® (naloxone HCl) Nasal Spray 4mg/spray product. The Court ruled in favor of the Defendants, Teva Pharmaceuticals Industries...
May 26, 2020 04:05 pm ET
Opiant Pharmaceuticals to Present at the 2020 Jefferies Virtual Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr. Roger Crystal, will present a company overview...
May 21, 2020 04:05 pm ET
Opiant Pharmaceuticals to Hold Virtual 2020 Annual Shareholder Meeting
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that it is changing the format of its 2020 annual meeting of shareholders (the...
May 12, 2020 04:05 pm ET
Opiant Pharmaceuticals Announces First Quarter 2020 Financial Results and Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2020, and provided a...
Apr 28, 2020 08:00 am ET
Opiant Pharmaceuticals to Report First Quarter 2020 Financial Results and Host Conference Call and Webcast on Tuesday, May 12
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31,...
Mar 04, 2020 04:05 pm ET
Opiant Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2019, and...
Feb 24, 2020 04:01 pm ET
Opiant Pharmaceuticals to Report Fourth Quarter 2019 Financial Results and Host Conference Call and Webcast on Wednesday, March 4
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the fourth quarter and year ended...
Jan 02, 2020 08:00 am ET
Opiant Pharmaceuticals Announces Development Collaboration with National Center for Advancing Translational Sciences for the Development of OPNT004 for the Treatment of Acute Cannabinoid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has signed a Letter of Intent with the National Center for Advancing...
Dec 12, 2019 04:05 pm ET
Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, Nasal Nalmef
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of approximately $2.4 million from...
Nov 12, 2019 04:05 pm ET
Opiant Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the third quarter and nine months ended September 30,...
Nov 05, 2019 08:00 am ET
Opiant Pharmaceuticals to Report Third Quarter 2019 Financial Results and Host Conference Call and Webcast on Tuesday, November 12
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the third quarter and nine months...
Oct 10, 2019 08:00 am ET
Opiant Pharmaceuticals to Host a Research & Development Meeting on Emerging Therapeutics for the Treatment of Addiction and Drug Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that Chief Executive Officer, Roger Crystal, M.D., and Chief Scientific Officer,...
Sep 24, 2019 04:05 pm ET
Opiant Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that it will present at the 2019 Cantor Global Healthcare Conference, taking place...
Sep 17, 2019 08:00 am ET
Opiant Pharmaceuticals Strengthens Management Team with Appointments of Chief Commercial Officer and General Counsel
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced the appointments of Aziz Mottiwala as Opiant’s Chief Commercial Officer, and Rahsaan...
Aug 27, 2019 04:30 pm ET
Opiant Pharmaceuticals Announces Presentations at Two Upcoming Investor Conferences
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, will present at the following upcoming investor conferences: 2019 Wells Fargo Securities Healthcare...
Aug 08, 2019 04:05 pm ET
Opiant Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the second quarter and six months ended June 30, 2019 and...
Jul 30, 2019 04:30 pm ET
Opiant Pharmaceuticals to Report Second Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, August 8
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the second quarter and six months ended...
Jul 23, 2019 08:00 am ET
Opiant Pharmaceuticals Expands Partnership with Sanofi, Signs Agreement for Manufacturing OPNT004 for Treatment of Acute Cannabinoid Overdose
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has signed an agreement with Sanofi (NYSE:SNY) to manufacture Opiant’s investigational...
May 09, 2019 04:05 pm ET
Opiant Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the three months ended March 31, 2019, and provided a corporate...
Apr 30, 2019 04:05 pm ET
Opiant Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on Thursday, May 9
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, 2019,...
Apr 08, 2019 08:00 am ET
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT003, Nasal Nalmefene, for Treatment of Synthetic Opioid Overdose
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic (PK) data for OPNT003, nasal nalmefene containing Intravail®...
Apr 03, 2019 08:00 am ET
Opiant Pharmaceuticals Announces Publication of Clinical Pharmacokinetic Data Supporting Potential of OPNT002, Nasal Naltrexone, for Treatment of Alcohol Use Disorder
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that clinical pharmacokinetic data of OPNT002, nasal naltrexone containing Intravail® (dodecyl...
Apr 01, 2019 08:00 am ET
Opiant Pharmaceuticals Announces Award of Second Tranche of Approximately $3.0 Million from National Institutes of Health Grant for Development of OPNT003, Nasal Nalmefene, for Treatment of Opioid Ove
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, has been awarded the second tranche of $3.0 million from the total grant of approximately $7.4 million...
Mar 28, 2019 08:00 am ET
Opiant Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will provide a corporate...
Mar 21, 2019 04:05 pm ET
Opiant Pharmaceuticals, Inc. Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today reported financial results for the quarter and year ended December 31, 2018, and provided a...
Mar 18, 2019 04:05 pm ET
Opiant Pharmaceuticals to Report Fiscal 2018 Financial Results and Host Conference Call and Webcast on Thursday, March 21
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it will report its financial results for the year ended December 31, 2018, after...
Feb 21, 2019 04:05 pm ET
Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Phase 2 clinical trial evaluating OPNT001, a naloxone nasal spray for the treatment of...
Dec 26, 2018 08:00 am ET
Opiant Pharmaceuticals Licenses Novel CB-1 Receptor Antagonist for Treatment of Acute Cannabinoid Overdose from Sanofi
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that it has entered into an exclusive global licensing agreement with Sanofi (NYSE:SNY) for the...
Dec 24, 2018 08:00 am ET
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that its most recently issued U.S. Patent, No. 10,085,937, covering...
Nov 19, 2018 07:40 am ET
New Research: Key Drivers of Growth for Huttig Building Products, Stratus Properties, Manitex International, Marathon Patent Group, Medallion Financial, and Opiant Pharmaceuticals — Factors of Influen
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Huttig Building Products, Inc. (NASDAQ:HBP), Stratus Properties Inc....
Nov 07, 2018 04:05 pm ET
Opiant Pharmaceuticals, Inc. Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today reported financial results for the quarter and nine months ended September 30,...
Nov 05, 2018 08:00 am ET
Opiant Pharmaceuticals Announces Last Patient, Last Visit in Phase 2 Clinical Trial Evaluating OPNT001 in Bulimia Nervosa
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that the Last Patient, Last Visit (LPLV) occurred on November 2, 2018, in its...
Nov 01, 2018 08:00 am ET
Opiant Pharmaceuticals to Report Third Quarter 2018 Financial Results and Host Conference Call and Webcast on Wednesday, November 7th
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it will report its financial results for the third quarter and...
Oct 29, 2018 08:00 am ET
Opiant Pharmaceuticals Appoints Seasoned Pharmaceutical Executive Craig Collard to Board of Directors
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced the appointment of Craig A. Collard to its Board of Directors. Mr....
Oct 22, 2018 08:00 am ET
Opiant Pharmaceuticals to Participate in Opioid Panel at the BARDA Industry Day
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that Opiant’s Chief Scientific Officer, Phil Skolnick, Ph.D., D.Sc....
Oct 18, 2018 08:00 am ET
Opiant Pharmaceuticals Announces Receipt of National Institutes of Health Grant by Walter Reed Army Institute of Research and SUNY Upstate Medical University for Development of a Heroin Vaccine
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that researchers at the U.S. Military HIV Research Program (MHRP) at...
Sep 28, 2018 04:01 pm ET
Opiant Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, today announced the closing of its previously announced underwritten public offering of 811,764...
Sep 26, 2018 08:00 am ET
Opiant Pharmaceuticals to Present at the Cantor Global Healthcare Conference
Opiant Pharmaceuticals, Inc. (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will provide a...
Sep 25, 2018 09:26 am ET
Opiant Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug abuse, today announced the pricing of an underwritten public offering of 705,882 shares of its common stock...
Sep 24, 2018 04:01 pm ET
Opiant Pharmaceuticals Announces Proposed Public Offering of Common Stock
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it intends to offer and sell, subject to market and other conditions, shares...
Sep 20, 2018 04:05 pm ET
Opiant Pharmaceuticals Announces Contract with Biomedical Advanced Research and Development Authority for Up to $4.6 Million to Accelerate Development of OPNT003, Nasal Nalmefene, for Treatment of Opi
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has entered into a multi-year contract with potential funding up to a...
Sep 10, 2018 08:00 am ET
Opiant Pharmaceuticals, Inc. and Consort Medical plc Announce Manufacturing Agreement for OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, and Consort Medical plc (“Consort”) (LSE: CSRT), a leading contract development and...
Sep 04, 2018 08:00 am ET
Opiant Pharmaceuticals Announces Final Patient Enrolled in Phase 2 Clinical Trial Evaluating OPTN001 in Bulimia Nervosa
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it has completed patient enrollment in its Phase 2 clinical...
Aug 16, 2018 07:55 am ET
Investor Expectations to Drive Momentum within Capital Senior Living, Thermon Group, L.B. Foster, Anavex Life Sciences, Opiant Pharmaceuticals, and Huron Consulting Group — Discovering Underlying Fact
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Capital Senior Living Corporation (NYSE:CSU), Thermon Group Holdings, Inc....
Aug 09, 2018 04:01 pm ET
Opiant Pharmaceuticals, Inc. Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today reported financial results for the quarter and six months ended June 30, 2018,...
Aug 02, 2018 08:00 am ET
Opiant Pharmaceuticals to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on Thursday, August 9
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and drug overdose, today announced that it will report its financial results for the second quarter and...
Jun 25, 2018 04:05 pm ET
Opiant Pharmaceuticals Announces Receipt of First Tranche from National Institutes of Health Grant for Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that it has received the first tranche of $500,000 from the previously awarded grant of...
Jun 12, 2018 08:00 am ET
Opiant Pharmaceuticals Appoints Biotech and Pharmaceutical Industry Veteran Richard Daly to Board of Directors
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the appointment of Richard J. Daly as a non-executive director and a member of the Audit...
Jun 04, 2018 04:05 pm ET
Opiant Pharmaceuticals to Participate in Opioid Panel at the BIO International Convention
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, will participate in a panel...
May 29, 2018 08:00 am ET
Opiant Pharmaceuticals to Participate in The American Society of Clinical Psychopharmacology 2018 Annual Meeting
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Opiant’s Chief Executive Officer, and Phil Skolnick, Ph.D.,...
May 25, 2018 07:45 am ET
Report: Exploring Fundamental Drivers Behind Opiant Pharmaceuticals, American Railcar Industries, Omega Flex, Johnson Outdoors, Thermon Group, and Connecticut Water Service — New Horizons, Emerging Tr
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), American Railcar Industries,...
May 08, 2018 04:05 pm ET
Opiant Pharmaceuticals, Inc. Reports First Quarter 2018 Financial Results and Provides Corporate Update
Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the first quarter ended March 31, 2018, and provided a corporate...
May 03, 2018 08:00 am ET
Opiant Pharmaceuticals To Host Key Opinion Leader Meeting on Medications for Addictions and Related Disorders
Opiant Pharmaceuticals, Inc. ("Opiant") (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, will host a Key Opinion Leader (KOL) luncheon on Medications for Addictions and Related Disorders on...
Apr 03, 2018 08:00 am ET
Investor Expectations to Drive Momentum within Atrion, Curis, Independence Contract Drilling, Utah Medical Products, FutureFuel, and Opiant Pharmaceuticals — Discovering Underlying Factors of Influenc
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Atrion Corporation (NASDAQ:ATRI), Curis, Inc. (NASDAQ:CRIS),...
Mar 19, 2018 04:05 pm ET
Opiant Pharmaceuticals, Inc. to Present a Corporate Overview at the Oppenheimer 28th Annual Healthcare Conference
SANTA MONICA, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, announced today that Roger Crystal, MD., President and Chief Executive Officer, will provide a corporate...
Mar 07, 2018 04:05 pm ET
Opiant Pharmaceuticals, Inc. Reports Financial Results for August 1, 2017, Through December 31, 2017, and Provides Corporate Update
SANTA MONICA, Calif., March 07, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, following the recent approval by its Board of Directors of a resolution changing the Company’s...
Feb 22, 2018 08:00 am ET
Aegis Awarded Patent for Fast Acting Nasal Spray Opioid Blockers and Pain Medications
Aegis' Intravail® formulations of Fast Acting Opioid Blockers and Pain Medications Speed Absorption and Lengthen Time of Drug Overdose Rescue and Pain Relief
Feb 12, 2018 08:00 am ET
Opiant Pharmaceuticals Announces Development of OPNT003, Intranasal Nalmefene, for Treatment of Opioid Overdose
Based on FDA Feedback, Opiant Intends to Pursue 505 (b)(2) Development Pathway 
Feb 08, 2018 08:00 am ET
Opiant Pharmaceuticals to Record Approximately $11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN® Nasal Spray for Opioid Overdose
SANTA MONICA, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will record a total of approximately $11.7 million in royalty and...
Feb 01, 2018 07:40 am ET
Report: Exploring Fundamental Drivers Behind Bryn Mawr Bank, Utah Medical Products, Opiant Pharmaceuticals, Whiting Petroleum, International Business Machines, and QUALCOMM — New Horizons, Emerging Tr
NEW YORK, Feb. 01, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Bryn Mawr Bank Corporation (NASDAQ:BMTC), Utah...
Jan 02, 2018 04:01 pm ET
Opiant Pharmaceuticals Receives Approximately $5.3 Million of Cash from Exercise of Outstanding Warrants
SANTA MONICA, Calif., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced the receipt of approximately $5.3 million of cash as a result of the...
Dec 20, 2017 08:00 am ET
Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN® Nasal Spray for Opioid Overdose
Opiant Expects to Receive 90% of NARCAN Sales-Related Royalty and Milestone Payments, Going Forward
Dec 19, 2017 10:00 am ET
Dec 19, 2017 08:00 am ET
Opiant Pharmaceuticals to Ring The Nasdaq Opening Bell on December 20, 2017
SANTA MONICA, Calif., Dec. 19, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that it will ring the Nasdaq Opening Bell on Wednesday, December 20, 2017.
Dec 18, 2017 08:00 am ET
Dec 04, 2017 04:05 pm ET
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
SANTA MONICA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported financial results for the fiscal first quarter ended October 31, 2017.
Oct 02, 2017 08:00 am ET
Titan Pharmaceuticals and Opiant Pharmaceuticals Collaborate to Explore a New Approach to Opioid Use Disorder Treatment
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2017 /PRNewswire/ -- Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) and Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) today announced a collaboration to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. The companies will conduct a feasibility assessment of a subcutaneous implant using Titan's proprietary ProNeura™ sustained release technology to administer an opioid antagonist. A product that delivers non-fluctuating, therapeutic levels of an opioid antagonist, continuously for up to
Sep 25, 2017 07:00 am ET
Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis
SANTA MONICA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc., (“Opiant”) (NASDAQ:OPNT), today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to testify before the President's Commission on Combating Drug Addiction and the Opioid Crisis and The Office of National Drug Control Policy leadership. Dr. Crystal will present to the commission, industry peers and meeting attendees regarding his experience and perspective on Innovative Pain Management and Prevention Measures for Diversion....
Sep 06, 2017 07:00 am ET
Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
SANTA MONICA, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that Roger Crystal, M.D., Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference in New York on Tuesday, September 12, 2017 at 8:45 a.m. ET....
Jul 27, 2017 08:44 am ET
Opiant CEO Roger Crystal Appears on Fox & Friends
SANTA MONICA, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions and eating disorders, today announced that Roger Crystal, M.D., Chief Executive Officer of Opiant, was featured this morning on Fox & Friends. The recurring segment, titled “Addiction in America,” details various aspects of the addiction crisis in the United States.  Dr. Crystal was interviewed by Fox & Friends host Ainsley Earhardt. The focus of the discussion was the national opioid ep...
Mar 09, 2017 07:00 am ET
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listings for Two New NARCAN® Nasal Spray Patents
SANTA MONICA, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today announced that its most recently issued U.S. patents, numbers 9,480,644 and 9,561,177 covering methods of use for NARCAN® Nasal Spray (“NARCAN”), are now listed in the U.S. Food and Drug Administration (FDA) publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book....
Jan 26, 2017 11:23 am ET
Opiant Pharmaceuticals, Inc. Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray
SANTA MONICA, Calif., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that the U.S. Food and Drug Administration has approved the 2mg formulation of NARCAN® Nasal Spray for opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. NARCAN® is partnered with and marketed in the U.S. by pr...
Jan 11, 2017 08:00 am ET
Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
- Plans to Initiate Phase 2 Study in Bulimia Nervosa -...
Dec 15, 2016 04:05 pm ET
Opiant Pharmaceuticals, Inc. Announces NARCAN® Nasal Spray Royalty Monetization
SANTA MONICA, Calif., Dec. 15, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today announced that it has signed a definitive agreement with SWK Holdings Corporation (“SWK”), whereby SWK will acquire rights to certain royalties and milestone payments related to the sales of NARCAN® Nasal Spray for the treatment of opioid overdose for up to $17.5 million. The Company received $13.7 million at closing and is eligible to receive an additio...
Nov 10, 2016 07:00 am ET
Opiant Pharmaceuticals, Inc. Announces Appointment of Thomas T. Thomas to Board of Directors
SANTA MONICA, Calif., Nov. 10, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the appointment of Thomas T. Thomas, CFA, to the company’s Board of Directors....
Oct 31, 2016 07:00 am ET
Opiant Pharmaceuticals, Inc. Reports Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial results for the fiscal fourth quarter and year ended July 31, 2016....
Oct 28, 2016 07:00 am ET
Opiant Pharmaceuticals, Inc. Licenses Heroin Vaccine From Walter Reed Army Institute of Research and National Institute on Drug Abuse
SANTA MONICA, Calif., Oct. 28, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that it has obtained exclusive development and commercialization rights to the heroin vaccine invented by scientists at the Walter Reed Army Institute of Research (WRAIR) and the National Institute on Drug Abuse (NIDA), a division of the National Institutes of Health (NIH).  ...
Oct 27, 2016 07:00 am ET
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for Narcan® Nasal Spray Patent
SANTA MONICA, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced today that its patent for NARCAN® Nasal Spray (“NARCAN”) is now listed in the U.S. Food and Drug Administration (FDA) publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, patent number 9468747....
Aug 18, 2016 08:45 am ET
Opiant Pharmaceuticals to Present at the Rodman & Renshaw Conference on September 13 in New York City
SANTA MONICA, Calif., Aug. 18, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13 from 3:00 to 3:25 pm ET. Dr. Roger Crystal, Chief Executive Officer, and Kevin Pollack, Chief Financial Officer, will be delivering an overview of the company and updating investors on the pipeline of products that it is developing for substance use, addi...
Jun 09, 2016 08:00 am ET
Opiant Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2016 Financial Results and Provides Corporate Update
SANTA MONICA, Calif., June 09, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, today reported financial results for the fiscal third quarter ended April 30, 2016....
May 12, 2016 08:00 am ET
Opiant Pharmaceuticals, Inc. Announces Appointments of Gabrielle A. Silver, M.D., and Ann MacDougall to Board of Directors
SANTA MONICA, Calif., May 12, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced the appointments of Gabrielle A. Silver, M.D., and Ann MacDougall, J.D., to the company’s Board of Directors....
May 06, 2016 08:30 am ET
Opiant Pharmaceuticals, Inc.’s Partner, Adapt Pharma Limited, Submits New Drug Submission for Naloxone Nasal Spray to Health Canada
SANTA MONICA, Calif., May 06, 2016 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for substance use, addictive and eating disorders, announced that its commercial partner for naloxone nasal spray for the emergency reversal of opioid overdose, Adapt Pharma Limited (“Adapt”), has submitted a new drug submission (NDS) for the product to Health Canada....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.